Here are five points:
1. The shares, however, lost 0.95 percent in the past five trading sessions.
2. Out of 11 analysts covering Integra Lifesciences, nine rate it “buy,” zero “sell,” while six rate it “hold.”
3. The shares have outperformed the S&P500 by 2.49 percent.
4. The company has a market cap of $2.36 billion.
5. Integra Lifesciences offers solutions for orthopedic extremity surgery, neurosurgery, spine surgery and reconstructive and general surgery.
More articles on devices:
AxioMed Freedom total disc shows high marks overseas: 5 things to know
Zimmer Biomet reports Q4 $0.22 per share dividend: 5 key notes
Zimmer Biomet stock among the most expensive right now: 4 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
